146 related articles for article (PubMed ID: 23896713)
21. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
22. Uterine endometrial carcinoma: 10 years' experience with long-term follow-up at a single Korean institution.
Lee EJ; Kim TJ; Choi CH; Lee JW; Lee JH; Bae DS; Park HM; Kim BG
Gynecol Obstet Invest; 2012; 74(4):313-9. PubMed ID: 23075517
[TBL] [Abstract][Full Text] [Related]
23. Endometrial stromal sarcoma: a clinicopathologic study.
Melilli GA; Di Vagno G; Greco P; Vimercati A; Loizzi V; Putignano G; Selvaggi L
Eur J Gynaecol Oncol; 1999; 20(1):33-4. PubMed ID: 10422678
[TBL] [Abstract][Full Text] [Related]
24. Endometrial stromal sarcoma-A retropsective analysis of factors affecting recurrence.
Agarwal R; Rajanbabu A; Nair IR; Satish C; Jose G; Unikrishnan UG
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():92-97. PubMed ID: 28738297
[TBL] [Abstract][Full Text] [Related]
25. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
26. Endometrial stromal sarcoma: a population-based analysis.
Chan JK; Kawar NM; Shin JY; Osann K; Chen LM; Powell CB; Kapp DS
Br J Cancer; 2008 Oct; 99(8):1210-5. PubMed ID: 18813312
[TBL] [Abstract][Full Text] [Related]
27. Surgery and adjuvant radiation therapy of endometrial stromal sarcoma.
Weitmann HD; Kucera H; Knocke TH; Pötter R
Wien Klin Wochenschr; 2002 Jan; 114(1-2):44-9. PubMed ID: 12407935
[TBL] [Abstract][Full Text] [Related]
28. Endometrial stromal sarcoma: a clinicopathologic study of 29 patients.
Rauh-Hain JA; Goodman A; Boruta DM; Schorge JO; Horowitz NS; del Carmen MG
J Reprod Med; 2014; 59(11-12):547-52. PubMed ID: 25552126
[TBL] [Abstract][Full Text] [Related]
29. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors and outcome in women with uterine sarcoma.
Denschlag D; Masoud I; Stanimir G; Gilbert L
Eur J Surg Oncol; 2007 Feb; 33(1):91-5. PubMed ID: 17174517
[TBL] [Abstract][Full Text] [Related]
32. Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.
Park JY; Baek MH; Park Y; Kim YT; Nam JH
Virchows Arch; 2018 Jul; 473(1):61-69. PubMed ID: 29869299
[TBL] [Abstract][Full Text] [Related]
33. Low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma: a comparative analysis emphasizing the importance of distinguishing between these two groups.
Bartosch C; Exposito MI; Lopes JM
Int J Surg Pathol; 2010 Aug; 18(4):286-91. PubMed ID: 19482859
[TBL] [Abstract][Full Text] [Related]
34. Endometrial stromal sarcoma: clinicopathological and immunophenotype study of 18 cases.
Vera AA; Guadarrama MB
Ann Diagn Pathol; 2011 Oct; 15(5):312-7. PubMed ID: 21652246
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
36. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
37. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.
Dhall D; Mertens R; Bresee C; Parakh R; Wang HL; Li M; Dhall G; Colquhoun SD; Ines D; Chung F; Yu R; Nissen NN; Wolin E
Hum Pathol; 2012 Apr; 43(4):489-95. PubMed ID: 21937080
[TBL] [Abstract][Full Text] [Related]
38. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
[TBL] [Abstract][Full Text] [Related]
39. The combined ratio of estrogen, progesterone, Ki-67, and P53 to predict the recurrence of endometrial cancer.
Jia M; Jiang P; Huang Z; Hu J; Deng Y; Hu Z
J Surg Oncol; 2020 Dec; 122(8):1808-1814. PubMed ID: 32920817
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
